Unknown PHASE2 INTERVENTIONAL 2-arm NCT04310176

Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION)

Randomized Phase 2 Study of Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

Sponsor: National Cancer Institute, Naples

Conditions Ras-mutated Metastatic Colorectal Cancer

Interventions 5-fluorouracil Bevacizumab Capecitabine Valproic acid mFOLFOX6 regimen mOXXEL regimen

Updated 8 times since 2020 Last updated: Nov 9, 2023 Started: May 24, 2019 Primary completion: Dec 31, 2023 Completion: Nov 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ras-mutated Metastatic Colorectal Cancer, this trial is ongoing. The trial is conducted by National Cancer Institute, Naples and has accumulated 8 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Apr 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Apr 2023 — Dec 2023 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Oct 2021 — Apr 2023 [monthly]

Recruiting PHASE2
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute, Naples

Data source: National Cancer Institute, Naples

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Napoli, Italy